Mumbai, May 14 -- Zydus Lifesciences has received the EIR report from the USFDA for

the inspection conducted at its API manufacturing facility located at Ambernath, Maharashtra.

This facility underwent an inspection from 10 to 14 February 2025, and had ended with NIL observations. The EIR report has classified it as No Action Indicated (NAI).

Published by HT Digital Content Services with permission from Capital Market....